376 related articles for article (PubMed ID: 27451324)
41. Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women.
Nappi RE; Kotek M; Brešt'anský A; Giordan N; Tramentozzi E
Climacteric; 2020 Oct; 23(5):519-524. PubMed ID: 32396754
[No Abstract] [Full Text] [Related]
42. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.
Palacios S; Nappi RE; Bruyniks N; Particco M; Panay N;
Climacteric; 2018 Jun; 21(3):286-291. PubMed ID: 29553288
[TBL] [Abstract][Full Text] [Related]
43. Viewing symptoms associated with Vulvovaginal Atrophy (VVA)/Genitourinary syndrome of menopause (GSM) through the estro-androgenic lens - Cluster analysis of a web-based Italian survey among women over 40.
Nappi RE; Di Carlo C; Cucinella L; Gambacciani M
Maturitas; 2020 Oct; 140():72-79. PubMed ID: 32616374
[TBL] [Abstract][Full Text] [Related]
44. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
45. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women.
Tersigni C; Di Simone N; Tempestilli E; Cianfrini F; Russo R; Moruzzi MC; Amar ID; Fiorelli A; Scambia G; Villa P
J Obstet Gynaecol; 2015; 35(8):835-8. PubMed ID: 25968636
[TBL] [Abstract][Full Text] [Related]
46. Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel.
Biglia N; Del Pup L; Masetti R; Villa P; Nappi RE
Support Care Cancer; 2020 Jun; 28(6):2507-2512. PubMed ID: 31970513
[TBL] [Abstract][Full Text] [Related]
47. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.
Salvatore S; Nappi RE; Zerbinati N; Calligaro A; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
Climacteric; 2014 Aug; 17(4):363-9. PubMed ID: 24605832
[TBL] [Abstract][Full Text] [Related]
48. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
Nappi RE; Panay N; Bruyniks N; Castelo-Branco C; De Villiers TJ; Simon JA
Climacteric; 2015 Apr; 18(2):233-40. PubMed ID: 25335119
[TBL] [Abstract][Full Text] [Related]
49. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
Nappi RE; Palacios S
Climacteric; 2014 Feb; 17(1):3-9. PubMed ID: 24423885
[TBL] [Abstract][Full Text] [Related]
50. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy.
Nappi RE; Murina F; Perrone G; Villa P; Biglia N
Minerva Ginecol; 2017 Aug; 69(4):370-380. PubMed ID: 28398023
[TBL] [Abstract][Full Text] [Related]
51. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
52. Management of Vaginal Atrophy: Implications from the REVIVE Survey.
Wysocki S; Kingsberg S; Krychman M
Clin Med Insights Reprod Health; 2014; 8():23-30. PubMed ID: 24987271
[TBL] [Abstract][Full Text] [Related]
53. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
[TBL] [Abstract][Full Text] [Related]
54. Modulation of vulvovaginal atrophy (VVA) by Gelam honey in bilateral oophorectomized rats.
Ismail NH; Ibrahim SF; Mokhtar MH; Yahaya A; Zulkefli AF; Ankasha SJ; Osman K
Front Endocrinol (Lausanne); 2023; 14():1031066. PubMed ID: 36923220
[TBL] [Abstract][Full Text] [Related]
55. Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy.
Constantine GD; Bruyniks N; Princic N; Huse D; Palmer L; Lenhart G; Blumentals WA; Nappi RE
Curr Med Res Opin; 2014 Jan; 30(1):143-8. PubMed ID: 24083677
[TBL] [Abstract][Full Text] [Related]
56. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
Davis SR; Robinson PJ; Jane F; White S; White M; Bell RJ
J Clin Endocrinol Metab; 2018 Nov; 103(11):4146-4154. PubMed ID: 30239842
[TBL] [Abstract][Full Text] [Related]
57. The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners.
Nappi RE; Kingsberg S; Maamari R; Simon J
J Sex Med; 2013 Sep; 10(9):2232-41. PubMed ID: 23809691
[TBL] [Abstract][Full Text] [Related]
58. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
59. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]